

Table S1 Stage of disease and cancer treatment for 28 cancer patients with COVID-19

Malignancy class	Cancer treatment at the time of SARS-CoV-2 diagnosis*	Cancer type	Cancer status	Hospitalization	Days of hospitalization	Death related to SARS-CoV-2
Solid tumor						
Lung cancer						
Patient 1	None	Adenocarcinoma of lung	Remission	Yes	2	No
Patient 2	None	Adenocarcinoma of lung	Stage IA	No	0	No
Breast cancer						
Patient 1	None	Invasive ductal carcinoma	Remission	Yes	39	No
Patient 2	Bevacizumab	Invasive ductal carcinoma	Metastatic	Yes	6	No
Patient 3	Capecitabine	Infiltrating carcinoma of breast	Metastatic	No	0	No
Patient 4	Pertuzumab , trastuzumab, tamoxifen	Infiltrating carcinoma of breast	Stage IA	No	0	No
Gastrointestinal tumor						
Patient 1	None	Rectal cancer	Metastatic	Yes	6	Yes
Patient 2	None	Adenocarcinoma of the pancreas	Stage IIB	No	0	No
Patient 3	None	Adenocarcinoma of the cecum	Stage IIB	No	0	No
Patient 4	Bevacizumab with irinotecan, leucovorin, 5-fluorouracil	Adenocarcinoma of the sigmoid colon	Metastatic	No	0	No
Patient 5	None	Liver cell carcinoma	Stage IB	No	0	No
Gynecologic cancer						
Patient 1	Cisplatin, radiation therapy	Mixed endometrial cancer	Stage IIIB	Yes	5	Yes
Prostate cancer						
Patient 1	None	Prostate cancer	Remission	No	0	No
Neuroendocrine tumor						
Patient 1	None	Neuroendocrine tumor of nasal cavity	Remission	Yes	5	No
Sarcoma						
Patient 1	Stereotactic body radiation therapy	Leiomyosarcoma of retroperitoneum	Stage IIIB	No	0	No
Skin cancer						
Patient 1	None	Basal cell carcinoma of skin	Remission	No	0	No
Hematologic malignancies						
Myelofibrosis						
Patient 1	Jakafi	Myeloproliferative neoplasm	Active—new diagnosis	Yes	9	No
Patient 2	Ruxolitinib and Aranesp	Myelodysplastic/myeloproliferative neoplasm	Active	Yes	19	No
Multiple myeloma						
Patient 1	Bortezomib, dexamethasone, cisplatin, doxorubicin, cyclophosphamide and etoposide	IgA kappa	Relapsed	Yes	5	No
Patient 2	Revlimid	IgG lambda	Remission	Yes	9	No
Patient 3	Carfilzomib, pomalidomide and dexamethasone	IgG kappa	Relapsed	Yes	28	No
Patient 4	Daratumumab, carfilzomib, cyclophosphamide, dexamethasone	IgA kappa	Relapsed	Yes	3	No
Patient 5	Daratumumab, lenalidomide and dexamethasone	IgG kappa	Relapsed	Yes	13	No
Leukemia						
Patient 1	None	Chronic lymphoid leukemia	Remission	Yes	28	
Patient 2	Ibrutinib	Chronic lymphoid leukemia	Relapsed	No	0	No
Lymphoma						
Patient 1	None	Hodgkin lymphoma	Remission	Yes	4	No
Patient 2	Rituximab and Ibrutinib	Mantle cell lymphoma	Active	No	0	No
Patient 3	None	Diffuse large B-cell lymphoma	Active—new diagnosis	No	0	No

*, treatment within 30 days prior to diagnosis.